For patients with heart failure with preserved ejection fraction (HFpEF), endovascular treatment (EVT) improves left ...

An ejection fraction >35% is unconventional to be considered "preserved," so the results of this trial are inconclusive on whether patients with heart failure and ejection fractions usually ...

In addition to improving heart failure symptoms, finerenone reduced the onset of new type 2 diabetes in patients with mildly ...

Data regarding the efficacy and safety of the nonsteroidal mineralocorticoid receptor antagonist finerenone in patients with heart failure and mildly reduced or preserved ejection fraction are needed.

For patients with heart failure with preserved ejection fraction (HFpEF), endovascular treatment (EVT) improves left ...

Phase 2 Clinical Trial in Patients with Heart Failure with Preserved Ejection Fraction Expected to Begin in Q4 2024SOUTH SAN ...

Novo Nordisk's Wegovy label update receives a positive opinion from the EMA's CHMP, highlighting improvements in heart ...

Cytokinetics presented positive Phase 1 trial data for CK-586, a potential heart failure treatment, showing safety, ...

TX45 was well-tolerated with no observed immunogenicity, and demonstrated a favorable PK/PD relationship which was used to identify doses for the ...

BAGSVAERD, Denmark I 19, 2024 I Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human ...

The weight-loss jab Wegovy has been hailed as an “absolute game-changer” after a new study showed that it relieved symptoms ...

Finerenone reduced the composite of total first and recurrent heart failure (HF ... in patients with HF and mildly reduced or preserved ejection fraction, according to an international clinical ...